ResMed Inc. 10-Q Summary: Period Ended December 31, 2008
Business Context and Reporting Period
This is a Quarterly Report (Form 10-Q) for ResMed Inc., a Delaware corporation designing, manufacturing, and marketing equipment for sleep-disordered breathing and respiratory disorders. The reporting period covers the three and six months ended December 31, 2008. The company operates globally with manufacturing in Australia, Singapore, France, and the U.S., and major sales sites in the U.S., Europe, and Australia.
Key Financial Metrics
| Metric | Three Months Ended Dec 31, 2008 | Six Months Ended Dec 31, 2008 |
|---|---|---|
| Net Revenues | $222.98 million | $440.91 million |
| Gross Profit | $131.03 million (59% margin) | $258.15 million (59% margin) |
| Net Income | $33.85 million | $61.88 million |
| Diluted EPS | $0.44 | $0.80 |
| Operating Cash Flow | $56.5 million (Quarterly estimate) | $124.40 million (Six Months) |
| Cash and Equivalents | $320.49 million (as of Dec 31, 2008) | |
| Total Debt | $152.90 million (Current: $67.55M; Long-term: $85.35M) | |
| Working Capital | $482.8 million |
Material Changes vs. Prior Period
- Revenue Growth: Net revenues increased 10% for the quarter and 14% for the six months compared to the prior year periods. Growth was driven by increased unit sales of flow generators, masks, and accessories, particularly in North and Latin America (up 23% for the quarter).
- Foreign Currency Impact: Unfavorable currency movements negatively impacted reported revenues by approximately $11.1 million for the quarter and $5.3 million for the six months. Excluding currency effects, revenue growth was 16% for the quarter and 15% for the six months.
- Profitability: Gross margin decreased slightly to 59% from 60% in the prior year, attributed to reduced average selling prices partially offset by cost savings and favorable product mix. Net income increased 26% for the quarter and 21% for the six months.
- Comprehensive Income: While net income was positive, comprehensive income was negative ($120.3 million loss for six months) due to significant foreign currency translation losses of $181.6 million.
- Investment Impairment: The company recognized a $1.1 million impairment loss on cost-method investments due to global financial market uncertainty.
Guidance, Outlook, and Risks
- Outlook: Management expects SG&A expenses to remain in the 30-32% range of net revenue and R&D expenses in the 6-7% range. The company is investing in new markets, including diabetes and cardiology, supported by new clinical guidelines linking sleep apnea to heart failure and diabetes.
- Liquidity: The company maintains strong liquidity with $320.5 million in cash. However, $5.0 million of investment securities (auction rate securities) are currently illiquid due to market conditions, though the company expects to hold them until a buyback offer from UBS matures in June 2010.
- Capital Expenditures: Significant capital spending ($61.9 million for six months) is ongoing for the construction of a new corporate headquarters in San Diego, with an estimated $30.5 million remaining to complete the project.
- Risks: Key risks include global economic slowdowns affecting customer purchasing, foreign currency exchange rate volatility, and the potential for further impairment of investments or goodwill. The company is currently in compliance with all debt covenants.
- Legal: Ongoing litigation includes a dispute with the University of Sydney regarding intellectual property and a German tax audit. Management does not expect these to have a material adverse effect.
Investor Verification Checklist
- Liquidity of Auction Rate Securities: Verify the status of the $5.0 million investment in auction rate securities and the terms of the UBS buyback offer scheduled for June 2010.
- Foreign Currency Exposure: Assess the impact of the strengthening U.S. dollar on future international revenue and the effectiveness of the company's hedging program.
- Debt Covenants: Confirm continued compliance with debt covenants, specifically the total debt to EBITDA ratio and fixed charge coverage ratio, given the new $50 million Tranche D loan facility.
- Product Mix and Margins: Monitor gross margin trends as the company introduces new products (e.g., VPAP IV, Swift LT) and manages pricing pressures.
- Capital Project Completion: Track the completion timeline and cost overruns for the new San Diego headquarters construction.